Rigel Pharmaceuticals Inc... (RIGL)
| Bid | 18.6 |
| Market Cap | 345.64M |
| Revenue (ttm) | 179.28M |
| Net Income (ttm) | 17.48M |
| EPS (ttm) | 0.99 |
| PE Ratio (ttm) | 19.54 |
| Forward PE | 10.96 |
| Analyst | Hold |
| Ask | 21 |
| Volume | 90,219 |
| Avg. Volume (20D) | 233,335 |
| Open | 18.97 |
| Previous Close | 18.72 |
| Day's Range | 18.93 - 19.53 |
| 52-Week Range | 7.48 - 29.82 |
| Beta | 1.32 |
About RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical t...
Analyst Forecast
According to 5 analyst ratings, the average rating for RIGL stock is "Hold." The 12-month stock price forecast is $25, which is an increase of 29.23% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago · seekingalpha.com
Rigel Pharmaceuticals: 3-Drug Company Reaches ProfitabilityRigel Pharmaceuticals: 3-Drug Company Reaches Profitability
1 month ago · seekingalpha.com
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call TranscriptRigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary. R...
